What is SKNV?
SKNV operates as an FDA-registered 503B outsourcing facility, specializing in the production of customized dermatological medications. Established in 2015, the company has focused on streamlining the pharmaceutical supply chain by directly offering tailored solutions that bypass intermediaries. This approach ensures that patients receive essential treatments with greater affordability and promptness. Adhering rigorously to Current Good Manufacturing Practices (CGMP), SKNV collaborates closely with healthcare providers to develop and deliver over 120 unique formulations, thereby enhancing patient care within the dermatology field.
How much funding has SKNV raised?
SKNV has raised a total of $35M across 1 funding round:
Private Equity
$35M
Private Equity (2022): $35M with participation from Accelmed Partners
Key Investors in SKNV
Accelmed Partners
Accelmed Partners is a private equity firm that likely focuses on investments within the healthcare and pharmaceutical sectors, potentially specializing in companies that offer innovative solutions or possess strong regulatory compliance.
What's next for SKNV?
The recent major strategic investment into SKNV signals a pivotal moment for the company, likely indicating a transition towards scaling operations and expanding its market reach. This capital infusion is expected to fuel further development of its specialized dermatological medication production capabilities and potentially broaden its network of healthcare provider collaborations. SKNV's focus on CGMP compliance and direct-to-provider models positions it for continued growth and influence in addressing pharmaceutical supply chain inefficiencies.
See full SKNV company page
